GlassScriptPhysician profile
Noelle A Rolle
NPI 1003249194
$9,383.69
in general payments reported to CMS, 2019-2025
36 companies · $1,438 in 2025
The $1,438 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,250 · 2020: $542 · 2021: $1,113 · 2022: $325 · 2023: $2,930 · 2024: $1,787 · 2025: $1,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955 · Consulting Fee: $1,950 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,955.14 |
| Consulting Fee | $1,950.00 |
| Education | $248.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,545.80 | 2019-2025 | Benlysta, Nucala, Bexsero |
| Abbvie INC. | $1,075.19 | 2019-2025 | |
| Amgen INC. | $976.78 | 2019-2025 | Evenity, Uplizna, Tavneos |
| Genzyme Corporation | $802.83 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $501.27 | 2021-2025 | Lupkynis |
| Pfizer INC. | $448.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.94 | 2019-2025 | Ofev |
| Lilly USA, LLC | $355.08 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $349.26 | 2023-2025 | Saphnelo, Tagrisso, Calquence |
| Ucb, INC. | $312.23 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $283.98 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $233.91 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $193.99 | 2023-2024 | |
| Horizon Therapeutics Plc | $149.42 | 2021 | |
| Mallinckrodt Hospital Products INC. | $78.95 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $66.50 | 2023-2024 | Ultomiris, Strensiq |
| Mallinckrodt Enterprises LLC | $54.44 | 2019 | |
| Janssen Scientific Affairs, LLC | $44.70 | 2020-2022 | |
| Sobi, INC | $43.67 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.37 | 2021-2025 | Ninlaro |
| Daiichi Sankyo INC. | $42.08 | 2024 | Injectafer |
| Genentech USA, INC. | $38.79 | 2024 | Lunsumio, Polivy, Columvi |
| Incyte Corporation | $37.00 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Fresenius Kabi USA, LLC | $30.25 | 2023 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $29.61 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $27.06 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $26.67 | 2024 | Lynparza, Keytruda |
| Eisai INC. | $25.66 | 2024 | |
| Exelixis INC. | $23.99 | 2024 | Cabometyx |
| Sandoz INC. | $18.59 | 2024 | |
| Karyopharm Therapeutics INC. | $17.73 | 2024 | Xpovio |
| Novo Nordisk INC | $16.90 | 2023 | Rybelsus, Ozempic |
| Radius Health, INC. | $14.78 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.37 | 2019 | |
| Aveo Pharmaceuticals, INC. | $13.19 | 2023 | Fotivda |
| Arbor Pharmaceuticals, INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Rolle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.